Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

The phase 2b AMP trials are testing whether the broadly neutralising antibody VRC01 prevents HIV-1 infection in two cohorts: women in sub-Saharan Africa, and men and transgender persons who have sex with men (MSM/TG) in the Americas and Switzerland. We used nonlinear mixed effects modelling of longi...

Full description

Bibliographic Details
Main Authors: Yunda Huang, Logashvari Naidoo, Lily Zhang, Lindsay N. Carpp, Erika Rudnicki, April Randhawa, Pedro Gonzales, Adrian McDermott, Julie Ledgerwood, Margarita M.Gomez Lorenzo, David Burns, Allan DeCamp, Michal Juraska, John Mascola, Srilatha Edupuganti, Nyaradzo Mgodi, Myron Cohen, Lawrence Corey, Philip Andrew, Shelly Karuna, Peter B. Gilbert, Kathryn Mngadi, Erica Lazarus
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:EBioMedicine
Subjects:
Antibody mediated prevention trials
Population pharmacokinetics
VRC01
Broadly neutralising antibodies
HIV-1
Online Access:http://www.sciencedirect.com/science/article/pii/S235239642030579X

Internet

http://www.sciencedirect.com/science/article/pii/S235239642030579X

Similar Items